{"filings":[{"id":94499,"accession_number":"0001661181-26-000007","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.","Net loss $53.2M ($0.44/sh) vs $18.8M loss ($0.17/sh) in Q1 2025; adjusted net loss $43.7M.","Adjusted EBITDA loss $48.2M vs $12.5M loss; gross margin collapsed to 29% from 73%.","FY2026 revenue guidance $270M-$310M, decline of 45%-52% from $564.2M in 2025.","Cash $92.1M, no debt; expects sequential improvement in Q2 and strong H2 growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":37228000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106927,"accession_number":"0001193125-26-076595","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis reports record Q4 2025 revenue $225M; FY2026 guidance implies 25-38% decline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product revenue $225.1M (+78% YoY); Advanced Wound Care $217.2M (+83% YoY).","Q4 net income $43.7M ($0.25/sh) vs $7.7M ($0.04/sh) a year ago; Adj. EBITDA $84.2M.","FY2025 net product revenue $563.0M (+17% YoY); net income $37.0M vs $0.9M in FY2024.","FY2026 total net revenue guidance $350M - $420M, a 25% to 38% decline from FY2025; expects Q1 drop then sequential growth.","Cash and equivalents $94.3M with no outstanding debt as of Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":564169000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106926,"accession_number":"0001193125-26-064270","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Organogenesis appoints Patrick McGuire as CAO; Francisco remains CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick McGuire, 40, appointed Chief Accounting Officer and principal accounting officer effective Feb 18, 2026; was VP Corporate Controller since Sep 2023.","Annual base salary raised to $345,000; no other compensation changes.","David Francisco ceases as principal accounting officer but stays as CFO and principal financial officer.","McGuire is a CPA and previously held roles at Cynosure (controller) and PwC (director)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123253,"accession_number":"0001193125-25-335425","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organogenesis extends Canton lease terms through 2032 with related-party landlords; rent escalates 3% annually","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended leases at 65 Dan Road and 150 Dan Road from Dec 31, 2027 to Dec 31, 2032, with an option to extend to Dec 31, 2034.","2027 annual rent: $1.61M (65 Dan Road) and $3.16M (150 Dan Road); first renewal year rent = 103% of 2027 rent or fair market value.","Audit Committee approved related-party transactions with >5% holders Alan Ades, Albert Erani, Dennis Erani, Glenn Nussdorf (director), and Robert Ades (director).","Rent increases 3% per year after first renewal year; appraisal/arbitration process if tenant rejects landlord's fair market determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123252,"accession_number":"0001193125-25-269654","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).","Net income $21.6M ($0.11 diluted EPS) vs $12.3M ($0.09) YoY; adjusted net income $23.2M.","Adjusted EBITDA $30.1M vs $13.4M YoY; operating income $20.7M vs $6.2M.","FY2025 revenue guidance raised to $500-525M (4-9% YoY); Adj. net income guided $21.5-38.4M.","Cash $64.4M, no debt; cash down from $136.2M due to operations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":338562000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139932,"accession_number":"0001193125-25-217810","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).","ReNu showed numerical improvement in baseline pain reduction vs first Phase 3 (-6.9 vs -6.0); safety profile favorable.","Statistically significant maintenance of function (p<0.0001) reported in second study.","Company to request pre-BLA meeting with FDA by end of October 2025 to discuss combined efficacy from both Phase 3 trials.","First Phase 3 met primary endpoint (difference -0.7, p=0.0177); ReNu has FDA RMAT designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139931,"accession_number":"0000950170-25-105032","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue down 23% to $100.8M; amends credit agreement, waives covenant test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $100.8M (down 23% YoY); Advanced Wound Care fell 25%, Surgical & Sports Med up 16%.","Net loss $9.4M ($0.10 per share) vs $17.0M loss a year ago; adjusted net loss $7.5M vs income $0.2M.","FY2025 guidance: revenue $480-510M (flat to +6%); adjusted EBITDA $31.1-61.9M.","Fourth Amendment to Credit Agreement waives Q2 2025 covenant test; must reset covenants by Sept 30, 2025; no additional borrowing until then.","Cash and restricted cash $73.7M, no debt; expects cash plus product sales to fund ops for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":187698000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157533,"accession_number":"0001193125-25-145767","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Organogenesis stockholders approve Series A conversion issuance and director elections at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of >20% of Class A common stock upon conversion of Series A Preferred at less than Nasdaq minimum price.","All nine director nominees elected; Garrett Lustig re-elected via Series A written consent with vote tallies of ~72M for.","Advisory 'say-on-pay' proposal approved with 67.1M votes for, 6.3M against.","Ratification of RSM US LLP as independent auditor for FY2025 passed with 103.6M votes for, 3.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157532,"accession_number":"0000950170-25-066930","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.","Net loss $18.8M ($0.17 loss per share) vs $2.1M loss in Q1 2024; adjusted EBITDA loss $12.5M vs income $2.6M.","Cash $110.5M, no debt; cash used in operations $19.9M vs $10.2M in prior year.","FY2025 revenue guidance reaffirmed at $480M-$535M; updated net income guidance $4.7M-$34.0M (from prior range).","ReNu BLA submission on track for end of 2025; second phase 3 study patient enrollment expected by end of Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":86693000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175908,"accession_number":"0001193125-25-065638","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organogenesis posts investor presentation with no disclosed material changes; details unavailable","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted investor presentation to its website on March 27, 2025.","Presentation is current as of March 27, 2025; no obligation to update.","No financial or operational specifics from the presentation were provided in the filing.","Presentation attached as Exhibit 99.1 but content not fully reproduced in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175907,"accession_number":"0000950170-25-029021","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).","Q4 net income $7.7M ($0.05 diluted EPS) vs net loss $0.6M; adjusted net income $8.8M vs $1.9M.","FY24 revenue $482.0M (+11%); net income $0.9M vs $4.9M; adjusted net income $20.5M vs $12.7M.","Cash $136.2M, zero debt (vs $104.3M cash and $66.2M net debt year-end 2023).","FY25 guidance: revenue $480-535M; net income $9.5-38.8M; Adj. EBITDA $43.6-83.2M; ReNu BLA submission targeted by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":482043000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192817,"accession_number":"0000950170-24-132248","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Organogenesis repurchases 500K shares from director trust at $4.057/sh for $2M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchase of 500,000 shares from GN 2016 Family Trust (related to director Glenn Nussdorf) at $4.057/share, total $2.03M.","Price based on 10-day trailing VWAP of common stock as of Nov 26, 2024.","Repurchase approved by Audit Committee and a Transaction Committee of the Board due to related-party nature.","Funded by proceeds from Nov 12, 2024 sale of Series A Convertible Preferred Stock to Avista Healthcare Partners.","Closing expected on or around December 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192816,"accession_number":"0000950170-24-130202","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Organogenesis signs 16.5-year lease for 122,000 sq ft RI biomanufacturing facility, base rent $43/sq ft from 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased 122,000 sq ft at 100 Technology Way, Smithfield, RI for biomanufacturing expansion.","Initial term ~16.5 years through May 2041; two 10-year renewal options.","Base rent $43/sq ft starting June 2026, 3% annual escalations; triple net lease.","Lease contingent on state/local tax incentives; termination right with $1.25M payment if not secured by March 2025.","Company continues to operate Canton, MA HQ and other facilities in US and Switzerland."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192815,"accession_number":"0001193125-24-256699","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","5.03","2.04","3.02","3.03","5.02","8.01","9.01"],"status":"ready","headline":"Organogenesis raises $130M convertible preferred, repurchases 7.4M shares, appoints Avista director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 130,000 shares of Series A Convertible Preferred Stock at $1,000/share for gross proceeds of $130M.","Net proceeds used for strategic growth, debt repayment, and repurchase of 7.4M common shares from directors at $3.1597/share (~$23.5M).","Preferred pays 8% annual dividend, compounded quarterly, payable in cash or PIK; conversion price initially $3.7917 (20% premium).","Company expects to prepay ~$62.5M term loan principal and interest on Nov 13, 2024, using offering proceeds.","Appointed Garrett Lustig (Avista Principal) to Board, increasing board size to twelve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192814,"accession_number":"0000950170-24-125331","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).","GAAP net income $12.3M ($0.09 diluted EPS) vs $3.2M ($0.02) YoY.","Adjusted EBITDA $13.4M, down from $16.0M; Non-GAAP operating income $7.1M vs $11.0M.","Cash $94.9M, net debt $62.1M; FY guidance: rev $455-480M, adj net income $6.7-18.4M.","CEO cites brand equity and work with policymakers on access solution."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":355387000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209240,"accession_number":"0000950170-24-093893","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).","Net loss $17.0M ($0.13/sh) vs net income $5.3M Q2 2023; included $18.8M impairment and $4.0M software write-down.","Adjusted EBITDA essentially flat at $15.6M; adjusted net income fell to $0.2M from $6.1M.","FY2024 revenue guidance reaffirmed $445-$470M; net loss guided $(27)-$(12)M; Adj. EBITDA $16-$35M.","Cash $90.5M, debt $63.5M; management cites near-term variability in skin substitutes market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":240210000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227177,"accession_number":"0001193125-24-165670","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 15.9M share increase to 2018 Equity Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; votes ranged from 41.5M to 68.4M for, with broker non-votes of 39.3M.","Advisory vote on executive compensation passed with 63.8M for, 5.9M against.","Amendment to 2018 Equity Incentive Plan adding 15,900,000 shares approved (52.0M for, 17.7M against).","Ratification of RSM US LLP as independent auditor for FY2024 passed (106.4M for, 2.6M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227176,"accession_number":"0000950170-24-056885","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis beats Q1 revenue guidance with $110.0M; net loss narrows to $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $110.0M, up 2% YoY, exceeding high-end of FY2024 guidance.","Advanced Wound Care revenue $103.9M (+3%); Surgical & Sports Medicine $6.1M (-9%).","GAAP net loss $2.1M ($0.02 EPS); adjusted net loss $1.4M; Adjusted EBITDA $2.6M.","FY2024 guidance reaffirmed: revenue $445M-$470M; adjusted EBITDA $15.8M-$35M.","Cash $89.3M, debt $64.9M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":109976000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227175,"accession_number":"0001193125-24-086129","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court dismisses securities fraud lawsuit against Organogenesis, CEO and CFO with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Eastern District of New York granted motion to dismiss on March 29, 2024.","All claims against Organogenesis, CEO, and CFO dismissed with prejudice, preventing refiling.","Lori Freedman, Chief Administrative and Legal Officer, expressed satisfaction with the ruling.","No financial impact or settlement amount disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246062,"accession_number":"0000950170-24-023059","cik":1661181,"company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).","Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.","FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.","FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.","Management highlights progress on ReNu program for knee osteoarthritis as key value driver."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":433140000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334553829.0225564,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}